AGC Biologics Announces the Groundbreaking of its New Facility at its Copenhagen, Denmark Site
by Matteo Pellegrino Published on 8/20/21 10:30 AM News
AGC Biologics Appoints Tony Fraij as the new General Manager/Site Head of the Longmont, Colorado Site
by Matteo Pellegrino Published on 8/9/21 10:00 PM News
AGC Biologics Acquires Commercial Facility, Expanding Cell & Gene Therapy Global Service Offerings
by Matteo Pellegrino Published on 8/5/21 9:00 AM News
AGC Biologics Appoints Kevin Ingham as the new General Manager/Site Head of their Seattle, Washington Site
by Matteo Pellegrino Published on 8/2/21 11:00 AM News
AGC Biologics Enters Agreement to Acquire Facility in Longmont, CO, Eyeing to Significantly Expand Their Cell and Gene Therapy Capabilities and Offerings
by Matteo Pellegrino Published on 7/1/21 9:00 AM News

Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III
by Matteo Pellegrino Published on 6/23/21 5:30 AM News
AGC Biologics’ Heidelberg Facility to Further Supply Plasmid DNA for COVID-19 Vaccine
by David Self Published on 6/7/21 7:00 AM News
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its partnership with BioNTech SE (Nasdaq BNTX) to further supply Plasmid DNA (pDNA) starting material for the Pfizer-BioNTech COVID-19 vaccine, at AGC’s Heidelberg, Germany facility.
AGC Inc. Receives Best Acquisition Award for Adding the Former MolMed into AGC Biologics
by David Self Published on 5/19/21 10:06 AM News
(SEATTLE), May 19, 2021 -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced their win of the M&A Award for Best Acquisition, Cross-Border into Italy, presented by KPMG, Fineurop Soditic, and others. This award is dedicated to showcasing the best of the Italian M&A market.
AGC Biologics Expands Partnership with Rocket Pharmaceuticals
by David Self Published on 4/20/21 6:53 AM News
(SEATTLE), April 20, 2021 – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it has expanded its partnership with Rocket Pharmaceuticals, a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders.
AGC Biologics Appoints Jun Takami to General Manager/Site Head of Their Chiba, Japan Site
by David Self Published on 4/8/21 7:00 AM News
(CHIBA), April 8, 2021 – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced the appointment of Jun Takami as the General Manager/Site Head, to lead the continued successful operations as well as continuous improvements at its Chiba, Japan site.